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                                                                   Abstract 
 
For therapeutic responses against various diseases especiallythose are infectious in nature and also 
malignant such as cancer; vaccineinduces cellular and humoral immune responses endowed with 
prophylactic measures by both structurally and physiologically, whichprovides front-line defense 
and opposes various environmental assaults to protect the skin which is an important part of the 
immune system.The delivery of water soluble compounds such as peptides, proteins and 
vaccines,transdermal route overcome the barrier properties of stratum corneum of the skin. The 
capillaries, lymphatic,blood and interstitial fluid within the dermis and epidermis where the dermis 
is the major site of fluid exchange in between the both the dermis and epidermis .So immunization 
through transdermal route is more effective to achieve therapeutic drug level besides sustained 
release of drug can also be achieved to have a prolonged action of drug delivery. In this review 
summarizes the different delivery strategies in order to improve thedelivery of transdermal 
vaccines along with the carrier systems and the adjuvants which can be used to overcome these 
confronts and thereby enhance the transdermal vaccination or delivery.Dendritic cells which is an 
essential component of the immune system and induces a stronger immune response for the 
transdermal route of delivery by processing microbial antigens which migrate into lymphatic 
capillaries to lymph nodes.Immunogenic materials are being protected during the delivery and 
facilitate specific target oriented delivery system along with incorporation of various types of 
adjuvant materials.Moreover transdermal patches may also improve competitiveness in a large 
market segment of which known examples are nitroglycerin patches in the field of cardiovascular, 
it was favorably introduced for more than 3o years within the market of nitrate and latest 
introduction of rivastigmine patches in the indication of Alzeheimer and dopamine 
patchesParkinson disease and restless leg syndrome which are acted as a agonist by the 
indication.(B. Boroojerdi; H.M. Wolff et al.2010).Besides trandsermal vaccination has developed 
vaccines like-hepatitis B(Deng et al,2011), Foot and Mouth disease 
vaccines(Smartvet,2012),Dendritic antitumor vaccines(Tendeelo et al,2001) which is yet 
todeveloped.However, transdermal system supports lifecycle management of approved drugs by 
empowering the patientsituation. 
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1 Introduction 
To deliver drug successfully and efficiently, drug delivery has been an aim of researchers for 
ages. As the skin is one of the most sophisticated areas due to its ease of access and 
ubiquity, it is a widely used organ for drug delivery. Although parenteral route provides the 
quickest therapeutic action for any drug, it is not so patient convenient. As almost every 
person who has gone through pinching of needles has found this route disadvantageous. The 
most common limitations are: 
i) Pain and phobia due to needle 
ii) Various infectious diseases which can be transmitted through use and repeated 
use of the same needle (Walter & Wright, 2010). 
A study has been made which results in 30% of adult suffer from needle phobia. (Andrew, 
Jeong, & Prausnitz, 2012). Moreover, significant populations are in unintentional injuries of 
the needle to both patient as well as the physician. It involves million of dollars- worth of 
additional medical treatment and raises transmitted infectious diseases ratevariably(Dahlan, 
Alapar, & Stickings, 2009) 
Due to the hazardous needle practices, the world Health Organization estimated 1.3 million 
deaths were caused. In fact estimation for the developing countries says 50% of the 
injections are unsafe and there are 800,000cases reported of needle injuries by medical 
professions each year.(Miller and Pisani, 1999) 
 
1.1 The Physiology and Anatomy of skin 
 
The skin which  is one of the largest organs which is mainly responsible for sustaining 
homeostasis by regulation, protection of underlying tissues, temperature, retardation of 
water loss, housing sensory receptors, synthesizing certain chemicals, and excreting wastes 
along with it. The skin comprises of an outer epidermis and adermis, associated to 
underlying tissue along the subcutaneous layer (hypodermis). The epidermis is built up of 
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stratified squamous epithelium and deficits blood vessels. It comprises melanocytes and is 
well nurtured along with dermal blood vessels. The epidermis is significant because it helps 
against loss of water, microorganisms, mechanical injury and chemicals. The dermis ties the 
epidermis to elementary tissues. The dermis comprises of connective tissue along with 
collagen as well as elastic fibers between a gel-like ground substance. Now the dermal blood 
vessels convey nutrients to uppermost layers of skin and assist to govern temperature. The 
dermis also keeps nerve fibers, hair follicles, sensory fibers, sebaceous glands and sweat 
glands. The subcutaneous layer (hypodermis) is consists of loose connective tissue and 
insulating adipose tissue. It connects the skin to elementary organs and that contains the 
blood vessels that conveys to the skin. The auxiliary organs of the skin consists sweat 
glands, hair follicles, sebaceous glands and nails.  
 
 
1.2 Immune system and its overview 
Immune system has been evolved in order to shield the host from pathogenic microbes 
which are themselves continually evolving. It generally helps the host to eradicate toxic and 
allergenic substances that penetrate through the mucosal surfaces. Central to the immune 
system’s capability a response to invading pathogens, toxin or allergen is distinguished self 
from non self. Both the innate and adaptive mechanisms are being used by the host to detect 
and eliminate pathogenic microorganisms as well as self-nonself discrimination is included. 
 
T-cells have been evolved to recognize foreign antigen along with self antigen as a 
molecular complex as a result self tolerance is maintained. Without having selftolerance, 
there is possibility of being attacked by autoimmune disease.  
Now the innate response shows that the first line of host defense with adaptive response 
becomes for active several days following antigen specific T and B cells have endured 
clonal expansion. Synergistic activity of both the innate and adaptive response are necessary 
to have an enact and full immune response.  
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Innate immune response acts as physical barrier for the pathogens and contains epithelial 
cell layers having tight junction. Now the epithelium of the gastrointestinal, respiratory, an 
genitourinary tracts along with the epithelial cilia which sweeps away the mucus layer 
allowing it to be constantly refreshed after contamination due to inhalation or ingestion of 
particles.Boroojerdi, Wolf, Braun and Blom (2010) found that the complement proteins 
defenses and ficolins present in biological fluids or can be released from cells as they are 
activated.Cytoplasm proteins whichhavemembrane bound receptors with that bind with 
molecular patterns that are stated on the surface of invading microbes. 
Adaptive immune system maintains specificity of its target antigens where the antigen 
receptors expressed on the surfaces of T and B lymphocytes. Adaptive response is ordinarily 
encoded by genes which are assembled by somatic re arrangement to form T-cell receptors 
and immunoglobulin genes.  
B-cell consists of approximately 15% peripheral blood leukocytes and produces 
immunoglobulin. 
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Figure 1.1: Overview of Immune system (Adapted from virtualmedicalcentre.com©) 
Adapted from: http://www.myvmc.com 
 
 
1.3Vaccine Terminology 
A particular disease can be defined as a biological preparation which provides active 
acquired immunity assisted by Vaccine. A vaccine from killed or inactivated forms is 
typically comprises of a disease-causative microorganism that is often made of the microbe, 
its toxins or one of its surface proteins.  It has been found out that the body's immune system 
is excited by this agent to identify it as threat, and destroy it, and maintains an account of it, 
and any such consecutive similar infection can be more easily identified by the immune 
system and destructed(Nir, Paz, & Sabo, 2003). 
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1.4Vaccination Terminology 
Administering of an antigenic material (vaccine) within a living mechanism, 
vaccinationwhich can be defined by this process in which individual’s immune system is to 
cause excitation, the clinical effect desired of an so that it can grow an adaptive immunity 
against the pathogen forming the vaccine. Diane, McAllister,Ping and Shawn (2003) has 
demonstrated that vaccination is the most ideal method of prevention for infectious diseases 
(V, wang, & Davis, 2003). 
 
1.5Types of Vaccination: 
 
I. Live, attenuated Vaccines 
II. Inactivated Vaccines 
III. Subunit Vaccines 
IV. Toxoid Vaccines 
V. Conjugate Vaccines 
VI. DNA Vaccines 
VII. Recombinant Vector Vaccines 
 
 
1.5.1Live, Attenuated Vaccines 
A living microbe which has been weakened in the lab so it cannot cause any disease 
includes live, attenuated vaccines.These vaccines are right “teachers” of the immune system, 
as live, attenuated vaccine is one of the closest things to a natural infection, strong antibody 
and cellular responses which often give lifelong immunity by only one or two doses are 
evoked by them. 
In spite of the benefits of live, attenuated vaccines, there are some disadvantages. The 
organisms used in live, attenuated vaccines are indifferent as it is the nature of living things 
to change, or mutate. The distant possibility exists that an attenuated microbe in the vaccine 
 
 
 
14  
might revert to a virulent form which causes disease. Besides, not everyone can securely 
receive live, attenuated vaccines. By their own protection, people who have disabled or 
damaged immune systems because they have undergone chemotherapy or have HIV, for 
example and cannot be given live vaccines. 
 
Figure 1.2: Influenza Treatment: Drugs and Live attenuated vaccines. 
Adapted from: http://employees.csbsju.edu 
 
 
1.5.2 Inactivated Vaccines 
The disease that affects microbe with, radiation, heat, or chemicals are the process of killing. 
Such vaccines are found to be safer and stable than live vaccines. The inactivated vaccines 
commonly do not require refrigeration and they can be readily stored and transported in a 
freeze-dried form that makes them available to people in developing countries. 
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But mostly they stimulate a weaker immune system response than do live vaccines. For this 
reason action has to be taken to go for several additional doses or booster shots, in order to 
maintain a person’s immunity. It could be a drawback in areas where people don’t have 
regular approach to health care and can’t get booster shots on spell. (Inactivated 
vaccine,2013; Retrieved from: http://www.vaccines.gov) 
1.5.3 Subunit Vaccines 
Subunit vaccines contain only the antigens that best stimulate the immune system in place of 
the whole microbe. In few cases, these vaccines utilize epitopes which is the very particular 
segments of the antigen where T cells or antibodies identify and bind to. As subunit vaccines 
include only the requisite antigens and not entire of the other molecules which make up the 
microbe, the risks of adverse reactions to the vaccine are lower. (Subunit vaccines, 2013; 
Retrieved from: http://www.vaccines.gov.) 
 
 
1.5.4Toxoid Vaccines 
A toxoid vaccine might be the response since bacteria that discharge toxins, or injurious 
chemicals .When a bacterial toxin becomes the main cause of illness and these vaccines are 
utilized. Inactivate toxins by compensating them with formalin which is a solution of 
formaldehyde and sterilized water which Scientists have found out. These kind of 
“detoxified” toxins, called toxoids, are secure for exercise in vaccines. 
While the immune system acquires a vaccine including a harmless toxoid, it assimilates to 
fight with the natural toxin. The immune system generates antibodies which lock onto and 
obstruct the toxin. Vaccines opposed to diphtheria and tetanus are models of toxoid 
vaccines. (Toxoid vaccine,2013; Retrieved from: http://www.vaccines.gov.) 
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Figure 1.3:TheDiptheria and Tetanus portion of the inactivated Toxoid vaccines. 
Adapted from: http://www2.cdc.gov 
1.5.5Conjugate Vaccines 
When a bacterium retain an external coating of sugar molecules named polysaccharides, as 
several toxic bacteria do and researchers making a conjugate vaccine for it will attempted. 
The immature immune systems of younger children and infants can’t identify or react to 
them on which Polysaccharide coatings conceal a bacterium’s antigens. Conjugate vaccines, 
a unique type of subunit vaccine, get almost this problem. 
T- Antigens or toxoids from a microbe that an infant’s immune system can identify to the 
polysaccharidesis connected by scientists while preparing a conjugate vaccine. The 
immature immune system responds to polysaccharide coatings and guard against the 
disease-causing bacterium is helped by the bond.  
The vaccines which mainly shields against Haemophilusinfluenzae type B (Hib) which is a 
conjugate vaccine. 
(Conjugatevaccine,2013;Retrievedfrom:http://www.vaccines.gov/more_info/types.) 
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Figure 1.4: A possible antiPseudomonoasaeruginosaConjugate vaccine. 
(Adapted from:http://www.cfww.org) 
 
 
 
1.5.6DNA Vaccines 
It is still within the experimental stages, on which these vaccines reveal great promise and so many 
types which has been tested in to humans.Fresh technological plane immunization is taken by DNA 
vaccine. These vaccines allot with both the full organism as well as its parts and get right down to 
the fundamentals, the microbes and its genetic substantial. In specific, DNA vaccines exercise the 
genes which code for all those significant antigens.(DNA Vaccines,2013; Retrieved from: 
http://www.vaccines.gov/more_info/types). 
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Figure 1.5: Study of DNA vaccine 
Adapted from:http://www.cfww.org 
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1.5.7 Recombinant Vector Vaccines 
Recombinant vector vaccines are basically experiential vaccines that are same to DNA 
vaccines, although they use an attenuated bacterium or virus in order to insert microbial 
DNA cells within the body. “Vector” relate to the virus or bacterium employed as the 
carrier. 
Mostly in this kind, viruses lock on to cells and introduce their genetic material within them. 
No-win the laboratory, scientists have undertaken benefit of this method. They have find out 
in which way to take the spacious genomes of definite safe or attenuated viruses and 
embedded portions of the genetic stuff from another microbe into them. Then the carrier 
viruses transport that microbial DNA into cells. Well recombinant vector vaccines exactly 
copy a natural infection and therefore do a better job of exciting the immune system. 
Attenuated bacteria where utilization is made as vectors.The antigens of other microbes on 
its exterior, the injected genetic material drives the bacteria to show here. Inducing an 
immune response the effect of the safe bacterium imitates a harmful microbe. 
Researchers are working on both viral-based and bacterial recombinant vector vaccines for 
measles, Rabies,HIV.(Recombinant vector vaccines,2013; Retrieved from: 
http://www.vaccines.gov/more_info/types). 
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Figure 1.6: Production of Recombinant HB Vaccine. 
Adapted from: https://www.ied.edu 
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Chapter 2 
RESEARCH METHODOLOGY 
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Research Methodology 
The summarization of the current status of transdermal delivery method of vaccination has 
been done in this article. The results were cross checked by searching Elsevier’s “Science 
Direct”, PubMed, SpringerLink. As well as other references and conference proceedings 
have also been included. Presently, there can be found a large benefit in expanding 
transdermal vaccinations are opposing many viral diseases as most of the pathogenic 
inclusion occurs through transdermal membranes. So, the effective vaccination measure can 
be taken via transdermal route to have a painless and desired efficacy of drug. However the 
development of transdermal vaccines, of infectious diseases or for oral immunotherapy-
tolerance, requires effective antigen delivery along with adjuvant systems, even if for 
prevention. To provide effective adaptive immunity by the stimulation mostly opposing 
infections and tumor growth which Corresponds the system that should protect the vaccine 
against the physical elimination as well as enzymatic degradation, targeted inductive sites 
and suitably the innate immune system is generated which involves M cells. Better 
transdermal vaccine delivery system which is an indicative advancement has newly been 
built in the progression of it. Although it has been already found out that drugs or antigens 
delivered via gene gun, electric charge, ultrasound frequency are well recognized by the 
immune system which is innate and are powerful inducers of immune system provides 
anxiety free delivery system. Various types of DNA and RNA transdermal vaccines are on 
the way of enriched development. The objective of this review is to discuss several distinct 
advents to induce transdermal immunity into vaccines accentuating on transdermal tissue 
targeting and novel immunization routes with a particular coverage on the delivery system. 
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Chapter 3 
METHODS OF TRANSDERMAL VACCINATION AND DISCUSSION 
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3.Classes of Transdermal drug delivery system 
There are various routes of drug administration. But the specific choice of delivery of drug 
mainly depends on diseases, physiological condition of the patient and the characteristics of 
the therapeutic compound. Lipophilicity is an important concept for the drug delivery within 
body with the molecular weight of < 500 Da in order to get liberated round the skin. The 
conveyance of the drugs with varying lipophilicity have been reported to improve by 
dynamic iontophoresis, mechanical commotion and energy dependent techniques such as 
ultrasound and needle-less injection. 
 
3.1Iontophoresis 
This may be also called as an Electromotive Drug Administration (EMDA) basically a 
needle-free injection mechanism which uses electric charge to transfer drugs or chemicals 
throughout the skin. An ionophoretic system includes a positive electrode (anode), a 
negative electrode or cathode, a battery, microprocessor and drug storage.The drug particle 
containing by the active electrode compartment and the return electrode is kept near the skin 
which completes the circuit. At that time a phenomenon is termed as electro migration and it 
is the dominant electro transport mechanism. Now the skin which acts as a cation selective 
membrane below physiological conditions and it governs to the formation of a conventional 
solvent flow in the anode to cathode course and which is known as electro osmosis and it is 
the insignificant instrument for the electrically aided transfer of cations.Neutral molecules 
are also being helped in electro transport from anode (Agarwal & Dhawan, 2009) 
The main usefulness of iontophoresis is that it is competent of leading the delivery kinetics. 
The extent and rate of the drug transfer is conditional on intensity and the duration profile of 
the flow entity applied. Now a days the challenge is being faced is that to provide a pre-
filled iontophoretic patch system similar to the convectional transdermal patches This 
process have got the signal of United States Food and Drug Administration and this 
classifies iontophoresis as one of the best efficient physical improvement technique for the 
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betterment of drug permeation over the skin(Jain, 2008)theelectrical current will be different 
as the matrices are different.  
This can be related to differences in viscosities, material electrical charge and porosities the 
migration of the drug under the influence of it(Gaur, Mishra, Purohit, & Dave, 2009) 
Delivery of high molecular weight compounds, like insulin has achieved through this 
technique in combination with chemical enhancers the larger peptides(Hansen, 2010) 
 
 
Figure 3.1: Iontophoresis delivery 
(adapted from Headache© 2012 Blackwell Publishing) 
 
 
3.1.1Hepatitis BVaccinationthroughIontophoresis: 
Hepatitis B vaccines were investigated in order to assess the penetration of vaccine under 
passive diffusion and iontophoresis conditions.  After removing the stratum corneum, the 
retention and permeation amount of hepatitis B vaccines increased. During administration of 
hepatitis B vaccine through the skin induction via Iontophoresis increases both of 
cumulative and retention time. Initial drug loading of 23 microg x mL(-1) and 46 microg x 
mL(-1) by application of iontophoresis significantly enhanced the permeation of hepatitis B 
vaccines (P < 0.05) by 2.7-folds and 6.6-folds for the intact skin, and by 1.6-folds and 1.8-
folds for the tape-stripped skin oresis (P < 0.05 ) respectively. The amount of skin retention 
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was nearly the same as passive diffusion for 24 h both from intact skin after applying 
iontophoresis for 6 hour. and tape-stripped skin respectively. However, hepatitis B vaccines 
may be improved byiontophoresis, which can be potentially used in the field of trans-
cutaneous immunization(Polat, Blanckstein, & Langer, 2010). 
 
3.1.2 Appliances based on velocity  
Here Gene gun is the instrument used. They drive vaccines from a restore into the stratum 
corneum layer of the skin. Small molecules and proteins from powder and liquid 
formulations are delivered by it.(Dahlan, Alpar, & Stickings, 2010) 
Compressed gas is generated at high velocity 100-200 m/s there is a nozzle having an orifice 
of diameter 50-360 μm from where the jet is propelled. The benefits of using needle-free 
devices comprehend accidental needle sticks, concerns over disposal, decreased amount of 
costly and hazardous wastes are prevented. The interstitial liquid may splash back from the 
skin and contaminate the nozzle so; the risk of cross contamination is not eliminated 
completely since.For multi dose drug delivery to the same individual, however, the multi-
use nozzle jet injectors are not used for mass vaccination nowadays. Sumavel® DosePro® 
needle-free delivery system (Zogenix, 2010) which was launched in 2010 for delivery of 
sumatripan and the Biojector® 2000 (Bioject Medical Technologies Inc., USA) which has 
been passed by FDA for intramuscular injections. This device is in its clinical trial phase for 
delivery of DNA vaccines are some examples of partially disposable devices. (Timmerman, 
Hermanson, Hobart, Taidi, & Caspar, 2002) 
The working of power jet injectors is akin to the liquid jet injectors since the power of jet 
injectors promote stronger immune responses because they transfer vaccines to the 
superficial layers of the skin(Prausnitz, Mikszta, Cornier, & Andrianov, 2009). 
 
Found out that the clinical tests of Phase I have provedPowderJect XR-1 ; the efficacy of 
which delivering gold particles coated with DNA for hepatitis and influenza.(Soderholm, 
Tjelle, Kjeken, Frelin, & Hogland, 2002) 
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Ballistic impact with the tissue can be sustained with the gold micro particles, attained a 
great success. The drawbacks associated with this mode is that it may give pain, bruising, 
burning sensations, tingling, discoloration, hyper-pigmentation, mild erythema at the site of 
injection. 
3.1.3Sonophoresis: 
Sonophoresis is another developing technology for the delivery of vaccines. Ultrasound of 
frequency (20-100) khz or high frequency ultrasound like 90, 7-0.16) kHz are used(Jeong, 
Andrews, & Prausnitz, 2012)Sonophoresis increases skin permeability mainly for the drugs 
such as insulin and heparin. For various low and high molecular weight drug can be induced. 
As it is costly process so the expenditure for preparing it must be cheap for availability of 
the use in future. This is an united effects with electroporation and iontophoresis, its exercise 
in gene therapy, hormone replacement, cardiovascular disorders, cancer therapy.(Polat, 
Blankschtein, & Langer, 2010)Sonoprep is the skin permeation device which applies 
frequency 55 khz for 30 seconds within the skin. When the desired level of permeability is 
obtained it stops automatically. The skin permeability is scaled by the stream moving 
through a return electrode. Although, stratumcorneum of the skin layer may get damaged 
due to breakdown of cavitations foams formed within the coupling medium (Polatet.al, 
2010). Extensive survey has been made to find out commercially available transdermal drug 
delivery system and along with the drugs for which they are being used. Following lists of 
transdermal delivery and drugs has been represented: 
Rabies vaccine (Blankschtein, Polat, & Langer, 2010)Influenza vaccine can be prepared by 
sonophoresis. 
 
3.1.4 Electroporation 
Transdermal delivery has opened up a new possibility to introduce larger molecules such as 
peptide hormones and vaccines as well as minigenes and RNAi etc. via the application of 
electroporation through the transdermal route. Among different geometrical arrangements 
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these devices include both non-puncturing surface electrodes as well as puncturing 
electrodes. To maximize transport, uptake and minimizing pain different electroporation 
protocols have been developed. Sonic, vibrational and thermal treatments are used to 
enhance the transport. 
 
 
 
Figure 3.2: Delivery of Vaccines by Electrporation. 
Adapted from:http://www.skin-care-forum.basf.com 
 
3.1.4.1Vaccination through Electroporation 
A. Dc (Dendritic cell) based vaccines: This type of vaccine is loaded with tumor antigens 
in which an approach has been made to prepare DC based tumor vaccine. Already in a 
study cytoplasm, which was expressed based on mRNA electroporation to efficiently 
expressed tumor antigens into DC which showed a improved transfection efficiency and 
induced a very low toxicity.So, electroporation  mRNA encoding tumor antigens  was a 
heavy technique to charge human dendritic cell with tumor antigen and can be served as 
future DC vaccine.(Tezel, Paliwal, & Shen, 2005) 
 
 
 
29  
B. Foot and mouth vaccines: Transdermal Vaccine projects of SmartVet’s are aimed at 
expanding the use of its versatile remote delivery technologies into the field of vaccines. 
Current research efforts are in the field of infectious diseases particularly. Foot 
andMouthDisease (FMD) on which the focus remains. Particularly the stratum corneum 
and underlying tight junctions, which the main challenge facing topical vaccines has 
been penetrating the protective barrier of the skin. The research showed that, this may 
facilitate antigen penetration via the intercellular pathway to the deeper layers of the skin 
deeper layers, which is uniformly accepted as an ideal target for antigen delivery are a 
highly immune competent zone. To generate strong immune responses to the topically 
applied antigens, VetCaps could further enhance the potential (Damme, Kafeja, Wielen, 
& Almagor, 2009) 
C. Infuenza vaccine:  Use of Nanopatch allowed a 100-fold reduction in the required dose 
of Fluvax® influenza vaccine in which preclinical in vivo studies.. Vaxxas’ 
Nanopatch™ vaccine delivery technology consists of a 1 cm2 silicone array that carries 
about 20,000 vaccine-coated microprojections that painlessly perforate the outer layers 
of the skin when applied with the associated applicator device, and deliver the vaccine 
directly to key immune (Damme, Kafeja, Wielen, & Almagor, 2009) 
3.2 Transdermal Nanoemulsion 
Recently researchers developed transdermal vaccines delivery improvement in the form of 
nano-size particulate, such as nanoemulsions, liposomes and nanoparticles. In vitro as well 
as in vivo absorption can be enhanced via this technique with good bioavailability. Now a 
model was selected which is named Artin-M, because the hydrophilic nature of both lectin 
and protein require same strategy for skin penetration(Amacker, Kammer, Rasi, Westerfield, 
& Moser, 2012) 
 
So both the lectin and protein were incorporated into the oil phase of nanoemulsioan as 
nanosize globules to improve the penetration of skin. This delivery is also appropriate for 
synergistic delivery of bovine serum albumin (BVA) which is a protein vaccine model. 
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3.3 Transdermal vaccination for immunization of Influenza via vaccine coated micro 
needle arrays: 
For simple administration fabrication of the micro scale needle utilizing minimal cost 
method for cheap mass output, for administration purpose a patch like format is made, 
perhaps by the patient to approach the resident dendritic cells themselves they inserted 
painlessly across the stratum corneum and into the skin’s epidermis and dermis. It increases 
immunogenic responses but needs specialized hands. The procedure begins with the micro 
needle is pushed manually towardfor a few minutes the skin is left in place meanwhile the 
vaccine coat, after which the micro needles are castaway disperses off within the skin. 
(Duffy, Weintraub, Vellozzi, & Destefano, 2010) 
 
 
3.4 Methods and Materials for fabrication of Micro needles 
Fabrication of microneedles is done with stainless steels (Trinity Brand Industries, 
Atlanta).By laser cutting and Electro polishing are done to clean the edges and to make the 
tip sharp dissolved in a solution containing glycerol ortho-phosphoric acid (85%) and 
deionized water in a ratio of 6:3:1 by volume .The geometry of the final micro needle where 
the spacing was made between the needles was 1575 mm.700 mm long, measured 170 mm 
by 55 mm in cross section at the base and tapered to a tip with a 5 mm radius of curvature 
for each needle(Almagor, Cormier, Mikszta, & Andrianov, 2009) 
 
 
3.4.1 Micro dip coating 
It is another method Micro needles with a specially formulated coating solution described 
before were coated using a dip-coating process (Donnelly, Berry, & Ulmer, 2003) includes 
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(w/v) carboxymethylcellulose sodium salt (low viscosity, USP grade, Carbo-Mer, San 
Diego, CA), 0.5% (w/v) Lutrol F-68 NF (BASF, Mt. Olive, NJ), 15% (w/v) D-(+)-
trehalosedihydrate contained by it and virus of 5 mg/ml inactivated A/ Aichi/2/68 (Aichi). 
The virus was concentrated by microfiltration using 300 kDa cutoff filters in order to reach 
high coating efficiency, (Vivaspin 500, Sartorius Stedim Biotech, Germany).Manually, the 
coating was done. To measure the amount of vaccine coated per row of microneedles, three 
rows from every batch of coated micro needles were drowned into 200 ml of PBS buffer per 
row for 5 min.Byestimating the concentration of protein in the solution by BCA protein 
assay (Pierce Biotechnology, Thermo fisher Scientific, Rockford, IL) coupled with a 
standardization curve formed using accepted concentrations of Aichi virus(Ellen, Jet, & 
Wilson, 2008) 
Discussions made on the development: Micro needle immunization technique provides 
better immunity as strong as that of Intramuscular injection. Studies showed that it provides 
more humoral and cellular immune response with single immunization. 
 As the study was performed within the mice bodies’ solid metal inactivated influenza 
virusmicro needle coated with conferred more than 99% protection regardless of lethal viral 
dispute andshort-lived antigen-secreting cells in the lungs and spleens of immunized mice as 
well as anti influenza memory B cell responses are inducted. It gives almost similar 
immunization as that of regular IM route having same grade of useful antibodies at high or 
low concentrations of antigen. 
 
3.5 Vaccination using cutaneous route applying micro needles coated with hepatitis C 
DNA vaccine 
The DNA vaccine that is much potent to produce vigorous humoral as well as cellular 
responses of immune. Characteristically it requires appreciably 5-10 mg of DNA producing 
a robust immune response in human. With the help of electroporation, potency can be 
increased to a great deal in humans and nonhuman who approximates three orders of 
magnitude in primatesbut the method is expensive than the micro needle delivery. 
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Microelectronics industry are there to fabricate micron-scale needles containing compounds 
that can be easily and painlessly delivered within the skin, applying techniques that are 
appropriate for economical massive production.Drug or vaccine introduced into the solid 
micro needle on the surface as a solid film following injection within the skin, interstitial 
fluid of the cutaneous rapidly discharges the film and liberates the drug or vaccine within the 
skin.   To vaccinate mice with inactivated influenza virus and guinea pigs along with 
ovalbumin the method was alreadyutlilized(Pilar, Jiskoot, & Riet, 2008)(Booms, Stucker, & 
Gambichler, 2006).To vaccinate mice, plasmid DNA has been used(Booms, Stucker, & 
Gambichler, 2006).Other procedure using empty miconeedle have been used to inoculate 
antigens within the skin ofhumans andanimals a number of antigens where humoral 
responses were create(Osterhuis, 2007). Electroporation combines smallpox DNA vaccine 
with micro needle to persuade humoral responses in nonhuman primates (Stucker et al, 
2006).Administration needs little or no training. It can also be prepared for self application, 
patch- like devices (Makidon, 2009). The hypothesis was examined utilizing a suitably 
developed vaccine of DNA encoded withnonstructural (NS) 3/4A protein hepatitis C virus 
which has previously been displayed to persuade powerful in vivo functional T-cell 
reactions in mice while transferred by intramuscular injection or gene gun, following by in 
vivo electroporation.The comparison has been made between 
 (1) Intramuscular DNA distribution by hypodermic injection, which is extensively used in 
animal studies but is basically useless in humans and 
 (2) Cutaneous approach using gene gun in humans that can be effective (Pathan, Seti, & 
Makidon, 2009) 
3.5.1 Discussion based on result using cutaneous route 
The lines ofmicro needles were planned to permit steady penetration within the skin of mice 
into the highly pliant. After coating with vitamin B2 rows (5 Microneedles) of micro needles 
were found to be uniformly coated. Afterwards, new micro needles) were covered with 
DNA, along every micro needle line was established in order to be coated with 1.6±0.2 mg 
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of DNA. 700 mm was) the design made for the micro needle, with 2-3mm thickness. Swine 
skin is a better anatomy for skin of human model. Skin was pierced with it sulforhodamine-
coated micro needles demonstrates that micro needles. Moreover, coated micro needles have 
been shown to have less or same 90% delivery efficiency. 
Mice were vaccinated along with 8 mg DNA using microneedles and 4 mg DNA using gene 
gun in order to determine whether cutaneous immunization of mice with micro needles with 
plasmid encoded hepatitis C virus NS3/4A protein could evoke a lytic cellular immune 
response. Verily,DNA-coated which was immunized with micro needles inducted the 
generation of lytic Cytoxic T- lymphocyte. Cell lyses was considerably greater following 
micro needle treatment contrasted with naive mice (P less than0.05).A cellular immune 
response which shows that micro needles liberated coated DNA that primed, most likely in 
the skin.However the overall study showed thatDNA plasmid which was expressed by the 
NS3/4A expression which can be liberated within the skin utilizing covered micro needles to 
evoke CTL’s priming which were same doses at same to gene gun, which refers that the 
responses of immune which was liberatedusing micro needles may be enough for vaccine 
applications of DNA(Rims, Pinsky, & Osdol, 2008). 
 
 
 
3.6 Topical immunization via Microporation 
This is an unique technique for painless and needle liberal transmission of adenovirus based 
vaccine. 
An investigation was made for genetic immunization utilizing replication-defective 
adenoviruses (rdAds) refers to replication defective adenoviruses as prototype vaccines 
using microporation as a device(Walter, Wright, & Fuller, 2010). 
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RdAds(replication defective adenoviruses) makes them appealing vectors for genetic 
vaccination possesses number of properties that are: 
 (1) They evoke potent cellular and humoralresponse.  
(2) 8kb of foreign DNA they can easily hold up to  
(3) Using basic molecular biology and tissue culture techniques they are readily manipulated 
and propagated. 
(4) Immunocompetent host have not been associated with the disease. (Walter et. al,2010) 
For topical delivery of rdAds is one of the noble methods. Hairless mice exhibit a hair 
follicle which are immune-competent and frequency (approx. 75 follicles/cm2) closer to 
human skin (approx.10 follicles/cm2).Though there are difference in hair follicle 10 fold 
density but same level of gene expression is observed following hairless mice which is 
microporated(Skountzou, Quan, Vzorov, & Gangadhara, 2007). 
AdLuc (adluciferase) was applied to both of the intact skin and microporated skin in order to 
determine whether microporation would develop the delivery of Ad vectors on to the skin. 
To measure luciferase gene expression then twenty-four hours later, the site of inoculation 
was eradicated and processed. The reproducibility of this technique where same levels of 
gene expression were observed in B6/129, BALB/c, and C57Bl/6 demonstrated to increase 
in luciferase activity which is compared to intact skin controls application of AdLuc in to 
microporated skin resulted in a 100–300-times. By applying vaccine to the intact skin- 
It is observed that hairless mice are more responsive than the hairy mice. 
For enhancing topical application of rdAd vectors in two settings: 
 
(1) Gene transfer to the skin 
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 (2) Genetic immunization; discussions can be made that the effectiveness of the 
microporationtechnology(Osdol, Rims, & Pinsky, 2008) 
 
3.7 Polysaccharide-based vaccines 
 
These are also introduced but lacked in immunogenicity conjugation of polysaccharide with 
a toxic antigen carrier renders activated T-cell Dependent antigens. As a result, the overall 
immunogenicity improves and the efficacy of the vaccine is enhanced.  IncludingPrevnarthis 
approach has led to the development of other polysaccharide the success of conjugate 
vaccines (Jonathan and Jeffrey, 2008)a quadri- valent meningococcal vaccine licensed in the 
U.S. in 2004.”(p. 36) a 7-valent pneumococcal conjugate vaccine approved in the U.S. in 
2000, and Menactra (Sanofi- Pasteur). Some form of gene tic engineering that we predict 
that the development of virtually all vaccines licensed from this point forward will 
involve.Allowingmanipulation of genes prior to rescue or regeneration of infectious 
organisms in culture the entire viral genomes can now be cloned into bacterial or yeast 
vectors. The rapid custom design of organisms for using in vaccines which has been enabled 
these methods.The virus DNA can be modified or parts of it can be omitted out to yield safer 
DNA strand. Using plasmid DNA instead of using diverse organisms or strains has become 
more common now-a-days. Currently, Influenza vaccines are developed by mainly 2 
methods involving random and molecular methods where desired vaccine strands are 
generated by trial and error and strictly controlling the production of the strands 
respectively. The molecular method is preferred as it gives the scope to eliminate several 
steps in the production process. Modified viruses are being used in cases of treatment of 
other viral diseases where they can cause immunogenic response towards the specified virus 
types. For instance, genetically modified adenoviruses are stripped off from the virulent 
genes and are used against other virus types such as HIV, Ebola and malaria virus. Scientists 
have found new ways to deal with viruses. Multiple proteins or vaccine cocktails can be 
introduced to treat multiple viruses in one host. Moreover, multiple types of vaccines made 
from the same type of virus with different type of proteins can show immunogenic property 
 
 
 
36  
against a number of viruses (Scarponi, Nassori, & Pavani, 2009)Instead of using live 
virus(Scarponi, Nasorri, & Pavani, 2009). Virus-like particles do not contain the necessary 
material to replicate (VLPs) are self-assembling constructs that express a viral antigen. 
Vaccines can be administered via different routes to greatly increase the effectiveness of the 
vaccines. Immunization action coalition has regulations to administer vaccines in the human 
body. 
 
Among the delivery systems of the vaccines,for a long time transdermal drug delivery has 
been used. It provides advantages in certain aspects- controlled release of the drug, reduced 
first-pass effect, prolonged duration of the steady-state level of the drug.  
 
 
3.8 Bird flu vaccine 
The studies that has been made so that expected vaccine strategies H5N1  can be identified 
as one of the most pathogenic constriction of the avian flu,the currently proposed 
technologies insufficient for rapid mass vaccination. H5N1 antigenwithin the antigen 
presenting cell (APC)-rich that is epidermal layer of the human skin in order to deliver the 
immunogen. The ability of the electrospinning method to organize a nanocomposite 
nonwoven mat which effectively encapsulates a peptide at derived from the H5-
hemagglutinin (HA) and contains its immunoreactivity through the processnowwhichthe 
study examines. To assure immune reactivity after has exposured of HA peptide to the 
conditions encountered in developing electrospunnanocomposite mats and just to quantitate 
levels of the immunogen on silicon wafer mark has been propose to employ for transdermal 
delivery on which the assay that have employed opt immune blotting with a slot blot 
apparatus in this process has permitted. Incorporation of numerous epitopes by a preferred 
antigen which hasrapid and efficient way to create the huge supplies of effective bird flu 
vaccines, in such case of its utilization and cost effectiveness which attempts the utilization 
of epitopes. 
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Influenza vaccination Pandemrix:  GlaxoSmithKline in Europe is manufacturer of 
Pandemrix was specifically produced for pandemic 2009 H1N1 influenza which is oil in 
water emulsion with adjuvant ASO3  
Pandemerix emulsion and suspension for influenza vaccine (H1N1)v contains split virion –
inactivated and adjuvanted. As a excipient it contains 5 microgram of Thimersal 
( Glaxosmithkline UK,2013). 
3.9 Ebola vaccine 
Ebola Vaccine Team which has developed an opportunity in order to discuss and address 
many important issues which are related to. To the broader aspects of global infectious 
disease prevention and control several key lessons, however, are generalized. 
Firstly, potential and ingenious funding strategies are required to ensure vaccines move 
efficiently from discovery and research through clinical trials and licensure to manufacturing 
as well as delivery, when ongoing the recent market-driven approach for vaccine 
development is not adequate to guard impoverished populations from emergent infectious 
diseases of pandemic or epidemic. 
Manufacturer’s profitability for vaccine is not assured. Secondly, enhanced international 
coordination and transparencyforEbola epidemic illustrates the need of West Africa, and 
approaching international regulatory outcomes for licensure of new vaccines particularly 
regarding which are approval processes for doing clinical trials in developing countries. 
Besides this process to identify community tryst needs in advance of a crisis situation, better 
readiness designs that need to be in place. Now the west Africa Ebola epidemic accents that 
need to further strengthen disease surveillance systems in the region and in other 
geographical areas within the continent and globally and finally.Several Ebola vaccines 
were in preclinical growth, owing to solid expenditures by many, the pharmaceutical 
industry,government agencies and private foundations at the onset of the Ebola epidemic in 
West Africa. But delivery of efficacious licensed products to be contrived areas has yet to 
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occurbefore work on product development platforms allowed relatively rapid progress to 
clinical trials for many vaccine candidates. On the feasibility and suitability of study plans to 
evaluate efficacy more quick validity assessment of these vaccines would have been 
possible if those had been evaluated for initial safety and immunogenicity in phase 1–2 
studies before the onset of the outbreak, and if there had been better consensus prior the 
epidemic(Moser, Amacker, Kammer, Rasi, Westerfield, & Zurbriggen, 2012)It is required to 
identify a developed methodwhich  emergents coronaviruses, such as severe acute 
respiratory syndrome coronavirus and middle Eastern respiratory syndrome coronavirus as 
well as other haemorrhagic fever viruses such as Marburg virus, Rift Valley fever virus, and 
Crimean-Congo haemorrhagic fever virus; emergent enteroviruses. Hendra virus and Nipah 
virus to ensure develop vaccines and other medical countermeasures for such pathogens that 
more robust research is initiated and supported (Amacker, Moser, Kammer, Rasi, & 
Westerfield, 2012) 
Mainly, three nucleoproteins obtained from the Zaire strain of the Ebola virus which shows 
conserved domains, along with two glycoproteins that helps in viral entry and mediated with 
Sudan/Gulu species which causative agent of hemorrhagic fever of Africa. To optimize 
expression in human cells ,the Ebola virus GP inserts have been modified  vaccine contain 
deletions in the transmembrane region of GP that were intended to eliminate potential 
cellular toxicity observed in the in vitro experiments using plasmids expressing the full-
length wild-type GPs, the Ebola virus GP genes expressed by plasmid DNA constructs 
within cell (Westerfield et al.2012). 
 
3.10 Mechanisms of Virosomeimmunopotentiation 
Whether the epitopes of the antigen are set on the surface of the virosome (PeviPRO™) the 
type of the elicited immune response to virosome formulations is dependent on (Moser et al, 
2007) or inside the virosome (PeviTER™) (Makidon, 2009). MHC II antigen 
presentation.PeviTER™   which are formulated antigens released in vivo not only a CD4+ 
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and CD8+ positive response but are also capable to induce a strong cytotoxic T-cell 
response (CTL ), the antigen is degraded within endosomes of the cell and, thus, creates 
predominantly. Virosomal encapsulation the MHC I pathway as the antigen is generated in a 
natural way into the cytosol of the antigen presenting cell, that assures a proper presentation 
of the antigens through MHCI pathway. 
Vaccines that are against hepatitis A (Epaxal®) and influenza (Inflexal®V)(Hartman, Kunzi, 
Herzog, & Lazar, 2009)have been validated the excellent characteristics of virosomes as an 
adjuvant as well as carrier system are now the registered. Togetherness,over 45 countries, 
and more than 10 million patients have been immunized by these two vaccines are accepted 
in to date. 
So, this new generation of vaccines gives additional advantages because the vaccines are 
effective even in immune-suppressed patients as well as in infants. Moreover, they have a 
high safety profile as enclosed viruses that do not replicate. 
 
3.11 Polymers used on transdermal vaccine Delivery 
 
In a transdermal drug delivery system polymers are considered as the backbone where a 
fabricated multi layer polymeric laminates a drug reservoir or a drug polymer matrix and 
that is sandwiched between two polymeric layers. Outer layer prevents loss of a drug and the 
inner layer functions as an adhesive or rate controlling membrane.(Ramario & Diwan, 1998) 
 
3.11.1 Polymers used intransdermalpatch 
The patches of transdermal vaccine may contain: 
A. Crosslinked polyethylene glycol network: Patches containing protein can be delivered 
by PEG with isocyaurinatemeans of urethane allophanate bond to obtain polymers 
network which are capable of swelling matrix buffered saline orethanolcontaining gels. 
(Bromberg, 1996) 
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B. Acrylic acid matrices: The patch is used with acrylic acid matrices along with 
plasticizers have been used to make drug polymer-matrix films for transdermal 
delivery.Eudragit RL PM, Eudragit S-100, Eudragit RS PM,andEudragit E-100(Costa, et 
al., 1997)u-dragit NE-40D (a copolymer of ethyl acrylate and methylmethacrylate), a 
non adhesive hydrophobic polymer, also has-been used as a former matrix. 
C. Ethyl Cellulose and polyvinylpyrrolidone: The patch of this delivery system contains 
EC and PVP matrix films with 30% dibutyl phthalate as a plasticizer. PVP acts an 
antinucleating agent and ethyl cellulose enhances its release rate constants (Ramaro, 
1998) 
D. HydroxyPropyl Methyl Cellulose: In the design of patches propranolol hydrochloride 
is used. Adequate solubility of the drug can be obtained. (Guyot & Fawaz, 1998) 
E. Polyurethrane:The patch mostly used this type is polyether as polyurethrane is prone to 
hydrolysis. Dirty or ugly scars can be removed by using polyurethrane patches(Fitri, 
2005) 
F. Acrylic polyisobutyline:This is a silicone based adhesives are mostly used in the design 
of transdermal patches(Barnart & Pftiser, 1998). Selection of adhesives depends on 
number of factors which includes patch design, drug formulation and skin compatibility. 
 
 
3.11.2.Polymers used in Needle 
 
A. Fabrication of Silicone microneddle: Silicon and chromium deposition within the 
needle is made and lithiographically patterned (20x20 arrays of 80 micrometer diameter  
dots with 150 micrometer center to center spacing).Microneedle fabrication is 
considered to be finished when the chromium masks become fully undercut and fell off 
the needle tips.(Wang, Park, & Allen, 2003) 
B. Polymer micromolds for solid needles: were fabricated from silicone or polymer 
substrates. The needle is 8mm thick and applied vacuum at 90 degree for 1 hour to 
remove any air bubble(Park, Allen, & Wang, 2003) 
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C. Fabrication of metal micro needles: Fabricated by electrode position on to polymer or 
silicon micromolds sputter coated with Ti/Cu seed layer (Allen, Wang, & Park, 2003)On 
hollow micro needle the mold adjacent to the outer surface on which needle tip is 
covered with powdered coating tape to protect it from being electroplated (Mcllister, 
2000). 
D. Fabrication of Polymer microneedle: This type of transdermal microneedle is made by 
polyglycolic acid, polylactic acid into the PDMS (Polydimethylsiloxone) at 120 degree 
to 250 degree celsius applying and peeling the molds off (Mcallister, 2000). 
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Conclusion:  
In the formation and discovery of new medicinal agents, the former twenty five years have 
seen an outbreak. The prosperous implementation s of many of these novel pharmaceuticals 
associated alterations in drug delivery systems have not only empowered, but have also 
allowed the formation of new medical treatments with prevailing drugs. One of the most 
important of these innovations the origination of transdermal delivery systems has become, 
which offered a number of benefits over the oral route. Significant impact this field has 
made on the administration of various pharmaceuticals; explore limitations of the current 
technology as well as discuss methods under research for overcoming those boundaries and 
the challenges beforehand,on this article, we tried to discuss.(Langer & Prausnitz, 2009).The 
word “transdermal” at clinicaltrials.gov responded 456 entries on exploration of April 2011 
(U.S National Institutes of Health 2011). For existing products that are available, the main 
focus of these tests is both novel products and novel delivery routes. These transdermal 
clinical trials involved the opportunity of some of which:  Insulin patch, Sufentanil patch for 
pain of chronic cancer, cessation of smoking with a high dose of nicotine patch 
Vareniclinefor fast,metabolizerspatchlike available for post-menopausal women for 
depression in the elderly and cocaine addiction Estrogen and testosterone are Selegiline 
patch is used.   
Though having some drawbacks, transdermal drug delivery gives lot of benefits competent 
of developing tolerant fitness and character connected with lifetime. Molecules which can be 
liberated through the skin, 1st and 2nd generation TDDS offer all these advantages though 
are limited in the scope. The capacity to transform TDDS in the close future and propose 
even more clinical benefits to the patient now Three Generations of Transdermal Delivery 
technologies that exists is doing advanced medical promotion to the technical field of 
medicine(Eady, Pop, & Maacgrath, 2008) 
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Future work: 
This system at future will replace all sorts of anxiety and fear of needle injections in order to 
apply a soothing way to deliver drugs for a quick systemic circulation.. As well as research 
are taking places for the invention  of new vaccines like’ Dendritic vaccine’ which acts as an 
antitumor vaccine are on the way to develop in its full form has already been discussed on 
this review paper. The development of this delivery system is not static but on the way to 
create a dynamic revolution. More valid researches are going on for the development of this 
delivery system. And unusual death due to needle infection can be avoided by this method. 
By attaining such dimensions in the medical technology will diversify the knowledge, field 
of research, safe use of drug and innovation of new process as well as equipment. 
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